GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Cyclically Adjusted PB Ratio

Immunotech Biopharm (HKSE:06978) Cyclically Adjusted PB Ratio : (As of Jun. 04, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Cyclically Adjusted PB Ratio?

Immunotech Biopharm does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Immunotech Biopharm Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Immunotech Biopharm's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunotech Biopharm Cyclically Adjusted PB Ratio Chart

Immunotech Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial - - - - -

Immunotech Biopharm Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunotech Biopharm's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Immunotech Biopharm's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunotech Biopharm's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Cyclically Adjusted PB Ratio falls into.


;
;

Immunotech Biopharm Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Immunotech Biopharm does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


Immunotech Biopharm  (HKSE:06978) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Immunotech Biopharm Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunotech Biopharm Business Description

Traded in Other Exchanges
N/A
Address
No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Executives
Jung Hyun Chul
Evodevo Ltd
Yan Kaijing 2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Cao Longxiang 2201 Interest of corporation controlled by you
Cao Fei 2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si 2501 Other
Yan Xijun 2501 Other
Wu Naifeng 2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited 2501 Other
Li Yunhui 2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
China Resources Company Limited 2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines